In conclusion, our study provides promising evidence that EFHD1 exerts potent antiproliferative and anti-metastatic effects in CRC, both in vitro and in vivo, by upregulating SIK3 to suppress EMT through modulation of the Hippo signaling pathway (Figure 7). The gene discussed is SIK3; the disease is colorectal carcinoma.